Breaking News Instant updates and real-time market news.

ARCT

Arcturus Therapeutics

$11.37

0.22 (1.97%)

, GSK

GlaxoSmithKline

$41.58

-0.13 (-0.31%)

07:46
08/31/19
08/31
07:46
08/31/19
07:46

Moderna, Translate strongest endorsement coming from Big Pharma, Barron's says

The strongest endorsement of Moderna (MRNA) and Translate Bio (TBIO) may have come from Big Pharma, with Astrazeneca (AZN) among the largest shareholders of the former and Merck (MRK) having two sperate drug-development deals with the company, Josh Nathan-Kazis writes in this week's edition of Barron's. Meanwhile, Takeda Pharmaceutical (TAK) owns 13.9% of Translate and GlaxoSmithKline (GSK) has another 6.3%, the author adds. One way to make hedged bets on mRNA is through companies such as AstraZeneca and Merck, which should profit if Moderna's technology begins to work out, the publication points out. Another public company, Arcturus Therapeutics (ARCT), is also pursuing mRNA therapies. Reference Link

ARCT

Arcturus Therapeutics

$11.37

0.22 (1.97%)

GSK

GlaxoSmithKline

$41.58

-0.13 (-0.31%)

TAK

Takeda Pharmaceutical

$16.85

0.28 (1.69%)

MRK

Merck

$86.37

-0.31 (-0.36%)

AZN

AstraZeneca

$45.06

-0.36 (-0.79%)

TBIO

Translate Bio

$9.04

-0.19 (-2.06%)

MRNA

Moderna

$15.74

0.55 (3.62%)

  • 06

    Sep

  • 09

    Sep

  • 09

    Sep

  • 12

    Sep

  • 16

    Sep

  • 16

    Sep

  • 18

    Sep

  • 20

    Sep

  • 24

    Sep

  • 25

    Sep

  • 02

    Oct

  • 03

    Oct

  • 29

    Oct

ARCT Arcturus Therapeutics
$11.37

0.22 (1.97%)

04/05/19
HCWC
04/05/19
INITIATION
Target $15
HCWC
Buy
Arcturus Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce started Arcturus Therapeutics with a Buy rating and $15 price target. The company is well positioned to realize the potential of mRNA therapeutics, Arce tells investors in a research note. The analyst believes Arcturus may initiate the first ever trial of an mRNA therapeutic dosed chronically via IV injection and views its "broad" RNA platform as "highly competitive and differentiated."
02/19/19
02/19/19
INITIATION

Fly Intel: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Southern Copper (SCCO) initiated with a Buy at Goldman Sachs. 2. Arcturus Therapeutics (ARCT) initiated with a Buy at Laidlaw. 3. HEXO Corp (HEXO) initiated with an Outperform at Oppenheimer. 4. Group 1 Automotive (GPI) and Lithia Motors (LAD) were initiated with an Overweight at JPMorgan, while Penske Automotive (PAG) and Asbury Automotive (ABG) were initiated with a Neutral, and Sonic Automotive (SAH) and AutoNation (AN) were initiated with an Underweight at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/19/19
LDLW
02/19/19
INITIATION
Target $19
LDLW
Buy
Arcturus Therapeutics initiated with a Buy at Laidlaw
Laidlaw analyst Yale Jen started Arcturus Therapeutics with a Buy rating and $19 price target. With two clinical products advancing and the potential of collaborations generating more products, the company's Lunar LNP platform "could tackle one of the crucial processes in nucleic acid medicine," Jen tells investors in a research note.
09/20/18
09/20/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Ralph Lauren (RL) upgraded to Neutral from Underweight at Piper Jaffray with analyst Erinn Murphy, who remains concerned about the sustainability of Ralph Lauren's sales group, saying earnings estimates are likely to continue to grind higher given the company's "sound" cost control and favorable margin mix shift. 2. Caterpillar (CAT) upgraded to Outperform from Neutral at Baird with analyst Mig Dobre saying he believes demand growth should continue into 2019. 3. Copart (CPRT) upgraded to Buy from Hold at Gabelli with analyst Matthew Paige saying he raised his valuation multiple to 15x EBITDA from 12x to reflect the premium he believes the stock deserves relative to KAR Auction Service (KAR) given its EBITDA margin advantage and his view that current market conditions better support the salvage auction business than wholesale. 4. Arcturus Therapeutics (ARCT) upgraded to Strong Buy from Buy at WBB Securities. 5. First BanCorp (FBP) upgraded to Buy from Neutral at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GSK GlaxoSmithKline
$41.58

-0.13 (-0.31%)

08/13/19
JPMS
08/13/19
INITIATION
JPMS
Neutral
GlaxoSmithKline reinstated with a Neutral at JPMorgan
JPMorgan analyst James Gordon reinstated coverage of GlaxoSmithKline with a Neutral rating and 1,700p price target. The analyst sees the stock near-term being Brexit and currency moves.
07/24/19
MSCO
07/24/19
NO CHANGE
MSCO
Warming could create need for up to $125B more vaccinations, says Morgan Stanley
Morgan Stanley analysts led by Matthew Harrison offered a report sizing the impact on biopharma from climate change. They conclude that warmer temperatures are likely to create more hospitable environments for disease transmission and they cite recent research that suggests 385M-725M more people than today may be exposed to infectious diseases such as dengue, Zika, chickungunya, and yellow fever by 2050. They estimate $50B-$125B of incremental vaccinations may be needed, but see the potential for that figure to be as high as $200B with branded pricing of more complicated vaccines. The companies best positioned to benefit from a rising need for infectious disease vaccines include Sanofi (SNY), GlaxoSmithKline (GSK), Moderna (MRNA), Merck (MRK), Johnson & Johnson's (JNJ) Janssen, Pfizer (PFE) and Takeda (TAK), according to Harrison and the team.
07/17/19
RAJA
07/17/19
NO CHANGE
RAJA
Investors shouldn't overreact to drug proposal headlines, says Raymond James
Raymond James analyst Chris Meekins noted that President Donald Trump has indicated an Executive Order on drug pricing is coming soon, but he believes investors "should be cautious not to overreact" to drug related proposal headlines as he "cannot think of a single proposal that was finalized and also survived a court challenge resulting in a negative impact on earnings" yet from the Trump Administration. Given the history of the current White House to date, Meekins said he is increasingly skeptical the Administration will get anything meaningful finalized and overcome legal challenges that will impact drugmakers' earnings before the 2020 election, he tells investors in a healthcare policy note. Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/11/19
WELS
07/11/19
NO CHANGE
WELS
Market right in seeing rebate news as risk to pharmaceuticals, says Wells Fargo
Most pharmaceuticals stocks are down today due to a number of factors, including reports that the Trump Administration is abandoning its plan to lower drug prices by eliminating or restricting pharmacy benefit manager rebating, Wells Fargo analyst David Maris tells investors in a research note. The analyst believes the market is correctly interpreting the move as a potential risk to drugmakers. The absence of a rebating fix "does not mean there will not be a plan to address drug prices, but perhaps a greater risk that the absence of a rebate fix will put additional pressure to come up with ways to actually lower prices in ways that could more greatly impact drug makers than the rebating fix would have," contends Maris. He points out that companies with large cash-pay components of their business, like Allergan (AGN), Establishment Labs (ESTA), Evolus (EOLS), GlaxoSmithKline (GSK), Perrigo (PRGO), Revance (RVNC) and Sientra (SIEN), do not seem to be under as much pressure today as some of their more generic or pharma-concentrated peers. Maris says his Outperform ratings on Allergan, Establishment and Sientra are in part due to their cash-pay concentration
TAK Takeda Pharmaceutical
$16.85

0.28 (1.69%)

08/15/19
DAIW
08/15/19
DOWNGRADE
DAIW
Neutral
Takeda Pharmaceutical downgraded to Neutral from Outperform at Daiwa
Daiwa analyst Kazuaki Hashiguchi downgraded Takeda Pharmaceutical to Neutral from Outperform with a price target of 3,700 yen, down from 4,500 yen.
03/19/19
GSCO
03/19/19
INITIATION
GSCO
Buy
Takeda Pharmaceutical reinstated with a Buy at Goldman Sachs
Goldman Sachs analyst Akinori Ueda reinstated Takeda with a Buy rating saying the Shire integration is the key catalyst to move shares higher.
03/19/19
03/19/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Casa Systems (CASA) initiated with a Buy at DA Davidson. 2. Sterling Bancorp (SBT) initiated with an Overweight at Piper Jaffray. 3. Takeda Pharmaceutical (TAK) reinstated with a Buy at Goldman Sachs. 4. CyberArk (CYBR) initiated with an Outperform at FBN Securities. 5. Varex Imaging (VREX) initiated with an Outperform at Northland. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/09/19
STFL
05/09/19
NO CHANGE
STFL
Buy
Novartis deal makes Aerie 'look like a steal' at current levels, says Stifel
Stifel analyst Annabel Samimy said Novartis' (NVS) agreement to buy Takeda's (TAK) dry eye product Xiidra for $3.4B upfront in cash and up to an additional $1.9B in potential milestone payments "clearly frames the value for innovative ophthalmologic assets" and makes shares of Aerie Pharmaceuticals (AERI) "look like a steal." Applying the same peak sales multiple that Novartis paid for Xiidra implies a market-value of greater than $6B for Aerie, said Samimy, who noted that she does not expect an immediate takeout of Aerie but remains a buyer of the shares.
MRK Merck
$86.37

-0.31 (-0.36%)

08/07/19
ARGS
08/07/19
NO CHANGE
Target $105
ARGS
Buy
Merck price target raised to $105 from $95 at Argus
Argus analyst David Toung raised his price target on Merck to $105 and kept his Buy rating after its "strong" Keytruda-driven Q2 earnings beat, also boosting his FY19 and FY20 EPS view by 16c and 10c to $4.89 and $5.35 respectively. The analyst sees Merck's "blockbuster" Keytruda drug on track for additional indications in the U.S., Japan, China and Europe, with additional growth drivers coming from its Gardasil, Bridion, Lynparza, and Lenvima programs.
08/16/19
08/16/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Merck (MRK) initiated with an Outperform at SVB Leerink. 2. DocuSign (DOCU) initiated with a Buy at DA Davidson. 3. iQIYI (IQ) initiated with an Underweight at JPMorgan. 4. Goodyear Tire (GT) initiated with an Outperform at Exane BNP Paribas. 5. BlackBerry (BB) initiated with a Neutral at Macquarie. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/15/19
LEER
08/15/19
INITIATION
Target $103
LEER
Outperform
Merck initiated with an Outperform at SVB Leerink
SVB Leerink analyst Daina Graybosch initiated Merck with an Outperform rating and $103 price target.
07/22/19
OPCO
07/22/19
DOWNGRADE
OPCO
Perform
Oppenheimer downgrades Intec Pharma after 'major setback' of trial miss
As previously reported, Oppenheimer analyst Jay Olson downgraded Intec Pharma (NTEC) to Perform from Outperform after the company announced "a major setback" as the ACCORDANCE study did not achieve statistical superiority to Sinemet on the primary endpoint of reduction in daily OFF time. He noted that the company still has additional opportunities with other drugs, including proprietary partnerships with Novartis (NVS) and Merck (MRK), but said the read across from AP-CD/LD to other AP applications in different diseases is uncertain following this morning's news.
AZN AstraZeneca
$45.06

-0.36 (-0.79%)

07/26/19
HCWC
07/26/19
NO CHANGE
HCWC
Amarin prepared to defend patents against Epanova launch, says H.C. Wainwright
After speaking with an intellectual property attorney, H.C. Wainwright analyst Andrew Fein believes Amarin (AMRN) has prepared itself to defend its patents for Vascepa against a possible launch of AstraZeneca's (AZN) omega-3 Epanova. The consultation revealed the FDA's Orange Book includes 25 patents listed for Vascepa, Fein tells investors in a research note. While, according to the IP attorney, Amarin's Orange Book patents do not appear to directly address Epanova, Amarin has a large patent portfolio in this space, says the analyst. Fein points out that Amarin could not hypothetically sue AstraZeneca for patent infringement until Epanova was made, used, or sold in a commercial context. These are not brand-generic circumstances between both companies, he writes. However, Fein thinks Amarin's patents could give it the upper hand and he reiterates a Buy rating on the shares with a $51 price target.
08/14/19
ARGS
08/14/19
NO CHANGE
Target $50
ARGS
Buy
AstraZeneca price target raised to $50 from $46 at Argus
Argus analyst John Eade raised his price target on AstraZeneca to $50 and kept his Buy rating, saying the stock has outperformed over the past quarter thanks to the pipeline developments that are returning the company to growth. The analyst notes that the company's future growth should be driven by its checkpoint inhibitor Imfinzi, and he sees the program tracking toward a billion-dollar blockbuster status from $338M reported in Q2. Eade further notes that AstraZeneca management has made efforts to address the ongoing pricing pressure and generic threats to its former blockbusters Nexium and Crestor by reducing costs and assembling a new drug pipeline.
08/13/19
BOFA
08/13/19
DOWNGRADE
Target $7
BOFA
Neutral
Clovis downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill Tazeen Ahmad downgraded Clovis (CLVS) to Neutral and lowered his price target to $7 from $13 after last week's release of positive topline results for its PARP inhibitor Lynparza to treat prostate cancer by the company's competitor AstraZeneca (AZN). The analyst notes that the Lynparza update alters his expectations in the prostate cancer market to assume a two-player landscape from day one, reducing his expectations for Clovis's Rubraca peak sales to $250M from $406M with peak U.S. BRCA penetration of 15%.
07/29/19
WBLR
07/29/19
NO CHANGE
WBLR
Outperform
Updates 'very positive' for upcoming Pieris presentation, says William Blair
Pieris Pharmaceuticals (PIRS) will present Phase Ib safety and efficacy results with PRS-060, an inhaled IL-4R alpha inhibitor, at the upcoming European Respiratory Society International Congress, held September 28 through October 2, William Blair analyst Matt Phipps tells investors in a research note. The poster presentation to be presented on October 1 is titled, "Multiple ascending dose study of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma," the analyst point out. In addition, AstraZeneca (AZN) plans to initiate a Phase II trial with AZD1402/PRS-060 in the second half of this year, according to its recent earnings presentation, adds Phipps. He views these updates as "very positive" for the upcoming presentation, and believes PRS-060 has "significant potential" in the treatment of asthma patients. Phipps keeps an Outperform rating on Pieris Pharmaceuticals.
TBIO Translate Bio
$9.04

-0.19 (-2.06%)

01/22/19
PIPR
01/22/19
NO CHANGE
Target $24
PIPR
Overweight
Translate clinical hold has no read-through to Moderna, says Piper Jaffray
Moderna's (MRNA) messenger RNA competitor Translate Bio (TBIO) announced this morning that the FDA placed a clinical hold on its Investigational New Drug Application for MRT5201 to treat ornithine transcarbamylase deficiency, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. Translate Bio also had a prior clinical IND hold on MRT5005 for cystic fibrosis due to manufacturing issues, adds the analyst. Tenthoff does not see read-through to Moderna's mRNA platform and pipeline from the news. The FDA accepted the company's IND for mRNA-3704 to treat orphan disease methylmalonic acidemia, and the Phase I/II study will begin soon, says the analyst. He reiterates an Overweight rating on Moderna with a $24 price target. The stock in midday trading is down 3% to $16.15.
06/18/19
06/18/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. ViewRay (VRAY) initiated with an Overweight at Piper Jaffray. 2. Premier (PINC) initiated with a Neutral at Guggenheim. 3. Stealth Biotherapeutics (MITO) initiated with a Buy at H.C. Wainwright. 4. Twilio (TWLO) initiated with a Buy at Needham. 5. Translate Bio (TBIO) initiated with a Buy at Roth Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/22/19
JEFF
07/22/19
INITIATION
Target $20
JEFF
Buy
Translate Bio initiated with a Buy at Jefferies
Jefferies analyst Eun Yang started Translate Bio with a Buy rating and $20 price target. The company's first human Phase 1/2 efficacy data in 2020, if positive, will provide "meaningful upside" in the shares, Yang tells investors in a research note.
06/18/19
ROTH
06/18/19
INITIATION
Target $25
ROTH
Buy
Translate Bio initiated with a Buy at Roth Capital
Roth Capital analyst Tony Butler started coverage of Translate Bio (TBIO) with a Buy rating and a $25 price target. The analyst believes that with its engineered mRNA and LPN delivery vehicles, Translate Bio's MRT platform has the advantages of enhanced stability, lower immunogenicity, tissue-specific delivery, and potentially scalable manufacturing. Butler also sees Sanofi (SNY) partnership providing resources and broadening the pipeline.
MRNA Moderna
$15.74

0.55 (3.62%)

05/29/19
OPCO
05/29/19
NO CHANGE
Target $31
OPCO
Outperform
Moderna price target raised to $31 from $27 at Oppenheimer
Oppenheimer analyst Hartaj Singh raised his price target for Moderna to $31 from $27 after spending time with management. The analyst was "consistently impressed" with the updates on safety, manufacturing, and increasing dosing experience of various Moderna therapeutics in different modalities. He reiterates an Outperform rating on the shares.
08/16/19
PIPR
08/16/19
NO CHANGE
Target $30
PIPR
Overweight
Moderna should be bought ahead of catalysts, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff recommends buying shares of Moderna on weakness ahead of the company's R&D day on September 12. Moderna has completed enrollment of the Phase I study of cytomegalovirus vaccine mRNA-1647 with data soon, and the company could also report preliminary Phase I data on intratumoral mRNA-2754 by the end of 2019, Tenthoff tells investors in a research note. Further, the analyst is focused on the Phase I chikungunya antibody mRNA-1944 data in Q4 for read-through to Moderna's orphan disease pipeline. He sees multiple clinical data readouts through the end of the year and reiterates an Overweight rating on the shares with a $30 price target.
06/20/19
PIPR
06/20/19
NO CHANGE
Target $30
PIPR
Overweight
Moderna recent weakness a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff recommends using the recent weakness in shares of Moderna as a buying opportunity. The stock is down 19% on increased volume since the initial public offering lock-up expiry on June 5, Tenthoff tells investors in a research note. The analyst is most focused on the Phase I chikungunya antibody data in the second half of 2019, which he believes will have read-through to Moderna's growing orphan disease pipeline. He reiterates an Overweight rating on the shares with a $30 price target.

TODAY'S FREE FLY STORIES

LOGI

Logitech

$40.72

0.66 (1.65%)

21:08
10/21/19
10/21
21:08
10/21/19
21:08
Earnings
Logitech backs FY20 revenue growth outlook in high single digits »

Backs FY20 operating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 04

    Nov

  • 05

    Nov

LOGI

Logitech

$40.72

0.66 (1.65%)

21:06
10/21/19
10/21
21:06
10/21/19
21:06
Earnings
Logitech reports Q2 adjusted EPS 50c, consensus 50c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 04

    Nov

  • 05

    Nov

VG

Vonage

$10.35

-0.04 (-0.38%)

21:05
10/21/19
10/21
21:05
10/21/19
21:05
Hot Stocks
Vonage accelerates expansion into Asia Pacific »

Vonage is continuing its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

PG

Procter & Gamble

$119.04

1.55 (1.32%)

, MCD

McDonald's

$209.85

1.365 (0.65%)

20:25
10/21/19
10/21
20:25
10/21/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PG

Procter & Gamble

$119.04

1.55 (1.32%)

MCD

McDonald's

$209.85

1.365 (0.65%)

UTX

United Technologies

$138.24

1.39 (1.02%)

NEE

NextEra Energy

$232.85

0.17 (0.07%)

LMT

Lockheed Martin

$373.16

0.54 (0.14%)

UPS

UPS

$118.56

1.23 (1.05%)

SHW

Sherwin-Williams

$551.04

-9.93 (-1.77%)

KMB

Kimberly-Clark

$139.31

2.01 (1.46%)

BIIB

Biogen

$223.57

3.52 (1.60%)

TRV

Travelers

$141.77

0.33 (0.23%)

PCAR

Paccar

$72.88

0.83 (1.15%)

FITB

Fifth Third

$28.04

0.71 (2.60%)

CNC

Centene

$45.83

-1.09 (-2.32%)

RF

Regions Financial

$16.08

0.305 (1.93%)

NUE

Nucor

$51.78

0.09 (0.17%)

HAS

Hasbro

$120.11

-1.78 (-1.46%)

TRU

TransUnion

$82.55

1.055 (1.29%)

DGX

Quest Diagnostics

$102.21

-0.465 (-0.45%)

IPG

Interpublic Group

$20.79

0.14 (0.68%)

HOG

Harley-Davidson

$37.14

0.555 (1.52%)

PII

Polaris Industries

$91.55

0.935 (1.03%)

SNV

Synovus

$36.30

1.005 (2.85%)

JBLU

JetBlue

$17.54

0.59 (3.48%)

GPK

Graphic Packaging

$14.86

0.205 (1.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 04

    Nov

  • 07

    Nov

  • 10

    Nov

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 19

    Nov

  • 04

    Dec

  • 07

    Dec

OISHY

Oil Search

$0.00

(0.00%)

20:01
10/21/19
10/21
20:01
10/21/19
20:01
Hot Stocks
Oil Search reports Q3 output 6.81MMBOE, down 1% qoq and down 10% yoy »

Cuts FY19 total…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EA

Electronic Arts

$95.81

0.63 (0.66%)

19:53
10/21/19
10/21
19:53
10/21/19
19:53
Downgrade
Electronic Arts rating change at Barclays »

Electronic Arts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 04

    Nov

  • 13

    Nov

TWTR

Twitter

$40.09

1.11 (2.85%)

, FB

Facebook

$189.82

3.865 (2.08%)

19:48
10/21/19
10/21
19:48
10/21/19
19:48
Hot Stocks
Twitter plans to update rules to address manipulated media on its platform »

The official Twitter…

TWTR

Twitter

$40.09

1.11 (2.85%)

FB

Facebook

$189.82

3.865 (2.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 27

    Oct

  • 30

    Oct

IRDM

Iridium

$24.23

-0.05 (-0.21%)

19:44
10/21/19
10/21
19:44
10/21/19
19:44
Hot Stocks
Iridium adds Intellian to Certus maritime portfolio »

Iridium announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

ERIC

Ericsson

$9.12

-0.075 (-0.82%)

, NVDA

Nvidia

$196.16

5.69 (2.99%)

19:29
10/21/19
10/21
19:29
10/21/19
19:29
Hot Stocks
Nvidia, Ericsson collaborate on virtualized 5G radio access technology »

NVIDIA (NVDA) and…

ERIC

Ericsson

$9.12

-0.075 (-0.82%)

NVDA

Nvidia

$196.16

5.69 (2.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 14

    Nov

  • 20

    Nov

NVDA

Nvidia

$196.16

5.69 (2.99%)

, MSFT

Microsoft

$138.43

1.09 (0.79%)

19:24
10/21/19
10/21
19:24
10/21/19
19:24
Hot Stocks
Nvidia announces technology collaboration with Microsoft »

NVIDIA (NVDA) with…

NVDA

Nvidia

$196.16

5.69 (2.99%)

MSFT

Microsoft

$138.43

1.09 (0.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 26

    Oct

  • 27

    Oct

  • 29

    Oct

  • 06

    Nov

  • 14

    Nov

  • 20

    Nov

  • 21

    Nov

USB

U.S. Bancorp

$56.19

1.125 (2.04%)

19:17
10/21/19
10/21
19:17
10/21/19
19:17
Periodicals
U.S. Bancorp to cut thousands of jobs from its branches, Bloomberg says »

U.S. Bancorp will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 15

    Jan

ADBE

Adobe

$266.84

1.42 (0.54%)

, AAPL

Apple

$240.49

4.2 (1.78%)

18:55
10/21/19
10/21
18:55
10/21/19
18:55
Periodicals
Adobe to roll out Illustrator app for iPad in 2020, Bloomberg reports »

Adobe (ADBE) has selected…

ADBE

Adobe

$266.84

1.42 (0.54%)

AAPL

Apple

$240.49

4.2 (1.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

  • 29

    Oct

  • 30

    Oct

  • 04

    Nov

  • 23

    Jan

NVDA

Nvidia

$196.16

5.69 (2.99%)

, IBM

IBM

$132.55

-1.55 (-1.16%)

18:43
10/21/19
10/21
18:43
10/21/19
18:43
Hot Stocks
Nvidia, Red Hat to deliver 5G wireless infrastructure to telecom industry »

Nvidia (NVDA) and Red Hat…

NVDA

Nvidia

$196.16

5.69 (2.99%)

IBM

IBM

$132.55

-1.55 (-1.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 27

    Oct

  • 14

    Nov

  • 20

    Nov

SMBC

Southern Missouri Bancorp

$36.24

0.38 (1.06%)

18:43
10/21/19
10/21
18:43
10/21/19
18:43
Earnings
Southern Missouri Bancorp sees Q1 EPS 85c, consensus 78c »

The company announced Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 28

    Oct

  • 13

    Nov

CDNS

Cadence Design

$66.67

1.07 (1.63%)

, AMTD

TD Ameritrade

$37.65

0.86 (2.34%)

18:36
10/21/19
10/21
18:36
10/21/19
18:36
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

CDNS

Cadence Design

$66.67

1.07 (1.63%)

AMTD

TD Ameritrade

$37.65

0.86 (2.34%)

HLX

Helix Energy

$8.32

0.31 (3.87%)

ZION

Zions Bancorp

$45.68

0.96 (2.15%)

STMP

Stamps.com

$76.12

0.55 (0.73%)

UPS

UPS

$118.56

1.23 (1.05%)

FBP

First BanCorp

$10.24

-0.015 (-0.15%)

VRTX

Vertex

$183.73

7.49 (4.25%)

KDMN

Kadmon

$3.08

0.17 (5.84%)

TACO

Del Taco

$9.66

0.26 (2.77%)

HXL

Hexcel

$74.59

-1.62 (-2.13%)

SITC

Site Centers

$15.27

0.175 (1.16%)

ADC

Agree Realty

$77.01

1.365 (1.80%)

CE

Celanese

$121.37

-0.3 (-0.25%)

HHC

Howard Hughes

$128.38

2.41 (1.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 21

    Oct

  • 21

    Oct

  • 21

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 04

    Nov

  • 05

    Nov

  • 06

    Nov

  • 07

    Nov

  • 11

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 14

    Nov

  • 19

    Nov

  • 19

    Mar

  • 22

    Oct

USB

U.S. Bancorp

$56.19

1.125 (2.04%)

18:31
10/21/19
10/21
18:31
10/21/19
18:31
Periodicals
U.S. Bancorp to cut thousands of jobs from its branches, Bloomberg says »

The report cites an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 15

    Jan

HLX

Helix Energy

$8.32

0.31 (3.87%)

18:16
10/21/19
10/21
18:16
10/21/19
18:16
Earnings
Helix Energy reports Q3 EPS 21c, consensus 16c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

  • 14

    Nov

CVX

Chevron

$116.66

1.87 (1.63%)

18:07
10/21/19
10/21
18:07
10/21/19
18:07
Periodicals
U.S. Treasury to let Chevron drill in Venezuela for 3 more months, Reuters says »

The U.S. Treasury…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

SFTBF

SoftBank

$0.00

(0.00%)

, WE

We Company

$0.00

(0.00%)

18:03
10/21/19
10/21
18:03
10/21/19
18:03
Periodicals
SoftBank's WeWork offer would lead to co-founder's exit, Reuters says »

SoftBank (SFTBF) offered…

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDEF

First Defiance Financial

$29.51

0.4 (1.37%)

17:59
10/21/19
10/21
17:59
10/21/19
17:59
Earnings
First Defiance Financial reports Q3 EPS 66c, consensus 60c »

Reports Q3 net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

UNFI

United Natural Foods

$6.91

0.35 (5.34%)

17:56
10/21/19
10/21
17:56
10/21/19
17:56
Recommendations
United Natural Foods analyst commentary  »

United Natural Foods…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCPT

Four Corners Property Trust

$28.35

0.135 (0.48%)

17:45
10/21/19
10/21
17:45
10/21/19
17:45
Hot Stocks
Four Corners Property Trust acquires Maryland property for $2M »

Four Corners Property…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

RTN

Raytheon

$202.21

2.41 (1.21%)

17:39
10/21/19
10/21
17:39
10/21/19
17:39
Hot Stocks
Raytheon awarded $128.45M Air Force contract for mobile sensors maintenance »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GNTY

Guaranty Bancshares

$30.22

0.02 (0.07%)

17:38
10/21/19
10/21
17:38
10/21/19
17:38
Earnings
Guaranty Bancshares reports Q3 EPS 65c, consensus 56c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$45.83

-1.09 (-2.32%)

, WCG

WellCare

$271.41

-3.13 (-1.14%)

17:32
10/21/19
10/21
17:32
10/21/19
17:32
Hot Stocks
Centene announces $500M share repurchase plan »

In a regulatory filing,…

CNC

Centene

$45.83

-1.09 (-2.32%)

WCG

WellCare

$271.41

-3.13 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.